HAVCR2 and hepatocellular carcinoma: Additionally, according to a recent study, higher TIM-3 expression on circulating T cells of HCC patients was associated with lower response rates to immune checkpoint-inhibitor treatment (PD-1/PD-L1 blockade) [21].